title: Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation--single center analysis.
abstract: Several protocols allow the successful ABO incompatible living-related kidney transplantation (ABO-ILKT), yet no single method has emerged as the best. We have made several substantial changes to our ABO-ILKT protocol over the past decade and a half and have attempted to determine whether the changes in immunosuppressive agents have resulted in a better outcome. We used methylprednisolone (MP), cyclosporine (CsA), azathioprine (AZ), antilymphocyte globulin (ALG) and deoxyspergualine (DSG) in the 105 cases of ABO-ILKT (group 1) between 1989 and 1999, and MP, tacrolimus (FK506), mycophenolate mofetil (MMF) in the 117 cases of ABO-ILKT (group 2) between 2000 and 2004. We compared the patient and graft survival rates as well as the incidence rate of acute rejection in these two eras, when different regimens were used. There were significant differences in the 1- and 5-year graft survival rates between groups 1 and 2 (1-year: 78% in group 1 vs. 94% in group 2; 5-year: 73% in group 1 vs. 90% in group 2, p = 0.008). Also, a higher incidence rate of acute rejection was significantly observed in group 1 (50/105, 48%) than in group 2 (18/117, 15%) (p < 0.001). We conclude that the FK/MMF combination regimen provides excellent graft survival results in ABO-ILKT.
authors.affiliation: Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. tgphide@gol.com
authors.forename: H
authors.initials: H
authors.lastname: Ishida
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
authors.forename: H
authors.initials: H
authors.lastname: Shirakawa
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Tokumoto
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Shimmura
authors.forename: K
authors.initials: K
authors.lastname: Setoguchi
authors.forename: D
authors.initials: D
authors.lastname: Toki
authors.forename: S
authors.initials: S
authors.lastname: Iida
authors.forename: S
authors.initials: S
authors.lastname: Teraoka
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Toma
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Tanabe
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D001323:Autoantibodies; D001787:Blood Group Incompatibility; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000276:immunology; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000017:ABO Blood-Group System; D001323:Autoantibodies; D007166:Immunosuppressive Agents